This invention provides a method for determining a subject's risk of memory impairment by analyzing plasma metabolite profiles. It involves comparing the subject's metabolite concentrations to normal values at multiple time points. Changes in specific metabolite levels indicate an increased risk of memory impairment, allowing for early intervention and treatment. This non-invasive blood test offers a potential screening tool for preclinical stages of cognitive decline.
BACKGROUND
Early detection of Alzheimer's disease and mild cognitive impairment is crucial for effective intervention, but current diagnostic methods are invasive, expensive, or limited in widespread applicability. This invention addresses the need for a simple, cost-effective blood-based biomarker test to identify individuals at risk of memory impairment before clinical symptoms appear.
Benefit
Market Application
Intellectual property status
- Granted Patent
Patent number : Patent No. 10,900,980
Where : USA
- Granted Patent
Patent number : Patent No. 11,808,774
Where : USA
Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.
Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Georgetown University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
